Development of high throughput screening assays and pilot screen for inhibitors of metalloproteases meprin α And β

Biopolymers - Peptide Science Section

Volumn 102, Issue 5, 2014, Pages 396-406

  Madoux, Franck ^a   Tredup, Claudia ^b   Spicer, Timothy P ^a   Scampavia, Louis ^a   Chase, Peter S ^a   Hodder, Peter S ^c   Fields, Gregg B ^d   Becker Pauly, Christoph ^b   Minond, Dmitriy ^d  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF KIEL   (Germany)

^c AMGEN INC   (United States)

^d TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

Actinonin; HTS; Meprin; NF449; Nhibitors; PPNDS; Suramin; Zinc metalloproteinase

Indexed keywords

NEURODEGENERATIVE DISEASES; BLOOD VESSELS; CORROSION INHIBITORS; THROUGHPUT; ZINC;

ACTINONIN; MEPRIN; METALLOPROTEINASES; NF449; NHIBITORS; PPNDS; SURAMIN; HTS;

DIAGNOSIS;

ACTINONIN; ANTHELMINTIC AGENT; ANTITRYPANOSOMAL AGENT; CISPLATIN; MEPRIN; MEPRIN BETA; METALLOPROTEINASE INHIBITOR; NF449; PYRIDOXAL 5' PHOSPHATE 6 2' NAPHTHYLAZO 6' NITRO 4' 8' DISULFATE; PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; SURAMIN; UNCLASSIFIED DRUG; MATRIX METALLOPROTEINASE INHIBITOR; MEPRIN B; METALLOPROTEINASE; MEPRIN ALPHA;

ANIMAL CELL; ARTICLE; ARTIFACT; BINDING SITE; COMPETITIVE INHIBITION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; REACTION TIME; REPRODUCIBILITY; ANTAGONISTS AND INHIBITORS; BIOASSAY; CHEMICAL DATABASE; CHEMISTRY; DRUG EFFECTS; ENZYME SPECIFICITY; PILOT STUDY; PROCEDURES; TIME FACTOR; ENZYME ACTIVE SITE; IC50; INHIBITION KINETICS;

BIOLOGICAL ASSAY; DATABASES, CHEMICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MATRIX METALLOPROTEINASE INHIBITORS; METALLOENDOPEPTIDASES; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS; SUBSTRATE SPECIFICITY; TIME FACTORS;

EID: 84924003296     PISSN: 00063525     EISSN: 10970282     Source Type: Journal    
DOI: 10.1002/bip.22527     Document Type: Article

References (27)

1. Sterchi, E. E.; Stocker, W.; Bond, J. S. Mol Aspects Med 2008, 29, 309-328.
2. Marchand, P.; Tang, J.; Bond, J. S. J Biol Chem 1994, 269, 15388-15393.
3. Bertenshaw, G. P.; Norcum, M. T.; Bond, J. S. J Biol Chem 2003, 278, 2522-2532.
4. Becker, C.; Kruse, M. N.; Slotty, K. A.; Kohler, D.; Harris, J. R.; Rosmann, S.; Sterchi, E. E.; Stocker, W. Biol Chem 2003, 384, 825-831.
5. Herzog, C.; Kaushal, G. P.;Haun, R. S. Cytokine 2005, 31, 394-403.
6. Kruse, M. N.; Becker, C.; Lottaz, D.; Kohler, D.; Yiallouros, I.; Krell, H.W.; Sterchi, E. E.; Stocker,W. Biochem J 2004, 378, 383-389.
7. Kronenberg, D.; Bruns, B. C.; Moali, C.; Vadon-Le Goff, S.; Sterchi, E. E.; Traupe, H.; Bohm, M.; Hulmes, D. J.; Stocker, W.; Becker-Pauly, C. J Invest Dermatol 2010, 130, 2727-2735.
8. Kohler, D.; Kruse, M.; Stocker, W.; Sterchi, E. E. FEBS Lett 2000, 465, 2-7.
9. Broder, C.; Arnold, P.; Vadon-Le Goff, S.; Konerding, M. A.; Bahr, K.; Muller, S.; Overall, C. M.; Bond, J. S.; Koudelka, T.; Tholey, A.; Hulmes, D. J.; Moali, C.; Becker-Pauly, C. Proc Natl Acad Sci USA 2013, 110, 14219-14224.
10. Broder, C.; Becker-Pauly, C. Biochem J 2013, 450, 253-264.
11. Bien, J.; Jefferson, T.; Causevic, M.; Jumpertz, T.; Munter, L.; Multhaup, G.; Weggen, S.; Becker-Pauly, C.; Pietrzik, C. U. J Biol Chem 2012, 287, 33304-33313.
12. Becker-Pauly, C.; Barre, O.; Schilling, O.; Auf dem Keller, U.; Ohler, A.; Broder, C.; Schutte, A.; Kappelhoff, R.; Stocker, W.; Overall, C. M. Mol Cell Proteomics 2011, 10, M111 009233.
13. Hachisu, M.; Hiranuma, T.; Murata, S.; Aoyagi, T.; Umezawa, H. Life Sci 1987, 41, 235-240.
14. Fields, G. B.; Lauer-Fields, J. L.; Liu, R.-q.; Barany, G. In Synthetic Peptides: A User's Guide; Grant, G. A., Ed.; W.H. Freeman & Co.: New York, 2001, p 93-219.
15. de Jong, G. I.; Buwalda, B.; Schuurman, T.; Luiten, P. G. Brain Res 1992, 596, 345-348.
16. Becker-Pauly, C.; Howel, M.; Walker, T.; Vlad, A.; Aufenvenne, K.; Oji, V.; Lottaz, D.; Sterchi, E. E.; Debela, M.; Magdolen, V.; Traupe, H.; Stocker, W. J Invest Dermatol 2007, 127, 1115-1125.
17. Zhang, J. H.; Chung, T. D.; Oldenburg, K. R. J Biomol Screen 1999, 4, 67-73.
18. Hodder, P.; Cassaday, J.; Peltier, R.; Berry, K.; Inglese, J.; Feuston, B.; Culberson, C.; Bleicher, L.; Cosford, N. D.; Bayly, C.; Suto, C.; Varney, M.; Strulovici, B. Anal Biochem 2003, 313, 246-254.
19. Janzen, W. P.; Popa-Burke, I. G. J Biomol Screen 2009, 14, 444-451.
20. Hu, W.; Luo, Q.; Wu, K.; Li, X.; Wang, F.; Chen, Y.; Ma, X.; Wang, J.; Liu, J.; Xiong, S.; Sadler, P. J. Chem Commun 2011, 47, 6006-6008.
21. Copeland, R. Evaluation of enzyme inhibitors in drug discovery; Wiley, 2005, Hoboken, New Jersey.
22. Lambrecht, G.; Braun, K.; Damer, M.; Ganso, M.; Hildebrandt, C.; Ullmann, H.; Kassack, M. U.; Nickel, P. Curr Pharm Des 2002, 8, 2371-2399.
23. Darsaud, A.; Chevrier, C.; Bourdon, L.; Dumas, M.; Buguet, A.; Bouteille, B. Trop Med Int Health 2004, 9, 83-91.
24. Anderson, J.; Fuglsang, H. Br J Ophthalmol 1978, 62, 450-457.
25. Hohenegger, M.; Waldhoer, M.; Beindl, W.; Boing, B.; Kreimeyer, A.; Nickel, P.; Nanoff, C.; Freissmuth, M. Proc Natl Acad Sci USA 1998, 95, 346-351.
26. Tan, G. T.; Wickramasinghe, A.; Verma, S.; Singh, R.; Hughes, S. H.; Pezzuto, J. M.; Baba, M.; Mohan, P. J Med Chem 1992, 35, 4846-4853.
27. Lambrecht, G.; Rettinger, J.; Baumert, H. G.; Czeche, S.; Damer, S.; Ganso, M.; Hildebrandt, C.; Niebel, B.; Spatz-Kumbel, G.; Schmalzing, G.;Mutschler, E. Eur J Pharmacol 2000, 387, R19-21.